Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)

NCT03659916 is registered in ClinicalTrials.gov with Albireo, an Ipsen Company as lead sponsor.

NCT NCT03659916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
Lead sponsor
Albireo, an Ipsen Company
Phase
Phase 3
Overall status
Completed
Start date
September 28, 2018
Completion date
December 2, 2025
Enrollment
116 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

progressive familial intrahepatic cholestasis